217 related articles for article (PubMed ID: 18817637)
1. Behçet's disease: recent advances in early diagnosis and effective treatment.
Calamia KT; Kaklamanis PG
Curr Rheumatol Rep; 2008 Oct; 10(5):349-55. PubMed ID: 18817637
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy of TNF-alpha antagonist and other immunomodulators in the treatment of patients with ophthalmologic manifestations of Behcet's disease and HLA B51 positive vasculitis].
Zlatanović G; Jovanović S; Veselinović D; Zivković M
Vojnosanit Pregl; 2012 Feb; 69(2):168-74. PubMed ID: 22500372
[TBL] [Abstract][Full Text] [Related]
3. Infliximab treatment for ocular and extraocular manifestations of Behçet's disease.
Accorinti M; Pirraglia MP; Paroli MP; Priori R; Conti F; Pivetti-Pezzi P
Jpn J Ophthalmol; 2007; 51(3):191-6. PubMed ID: 17554481
[TBL] [Abstract][Full Text] [Related]
4. Management of vascular Behçet's disease.
Alibaz-Oner F; Direskeneli H
Int J Rheum Dis; 2019 Jan; 22 Suppl 1():105-108. PubMed ID: 29665281
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy and safety of anti-tumor necrosis factor α monoclonal antibodies in 16 patients with severe/refractory vasculo Behcet's disease].
Li L; Liu JJ; Yu X; Wu D; Zhang SZ; Yang YJ; Zhou JX; Zeng XF; Zhang FC; Zheng WJ
Zhonghua Nei Ke Za Zhi; 2020 Apr; 59(4):303-308. PubMed ID: 32209197
[No Abstract] [Full Text] [Related]
6. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.
Levy-Clarke G; Jabs DA; Read RW; Rosenbaum JT; Vitale A; Van Gelder RN
Ophthalmology; 2014 Mar; 121(3):785-96.e3. PubMed ID: 24359625
[TBL] [Abstract][Full Text] [Related]
7. Behçet's syndrome: from aetiology to treatment.
Powell RJ
Adv Exp Med Biol; 2003; 528():481-6. PubMed ID: 12918749
[No Abstract] [Full Text] [Related]
8. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.
Calvo-Río V; Blanco R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Hernandez Garfella M; Valls Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero Coma M; Díaz-Llopis M; Gallego R; Salom D; García Serrano JL; Ortego N; Herreras JM; Fonollosa A; García-Aparicio AM; Maíz O; Blanco A; Torre I; Fernández-Espartero C; Jovani V; Peiteado-Lopez D; Pato E; Cruz J; Fernández-Cid C; Aurrecoechea E; García M; Caracuel MA; Montilla C; Atanes A; Hernandez FF; Insua S; González-Suárez S; Sánchez-Andrade A; Gamero F; Linares L; Romero-Bueno F; García AJ; Almodovar R; Minguez E; Carrasco Cubero C; Olive A; Vázquez J; Ruiz Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernández S; Rueda-Gotor J; González-Gay MA
Rheumatology (Oxford); 2014 Dec; 53(12):2223-31. PubMed ID: 24996907
[TBL] [Abstract][Full Text] [Related]
9. Effects of anti-TNF-alpha antibody infliximab in refractory entero-Behcet's disease.
Iwata S; Saito K; Yamaoka K; Tsujimura S; Nawata M; Suzuki K; Tanaka Y
Rheumatology (Oxford); 2009 Aug; 48(8):1012-3. PubMed ID: 19465589
[No Abstract] [Full Text] [Related]
10. The 2nd edition of consensus statements for the diagnosis and management of intestinal Behçet's disease: indication of anti-TNFα monoclonal antibodies.
Hisamatsu T; Ueno F; Matsumoto T; Kobayashi K; Koganei K; Kunisaki R; Hirai F; Nagahori M; Matsushita M; Kobayashi K; Kishimoto M; Takeno M; Tanaka M; Inoue N; Hibi T
J Gastroenterol; 2014 Jan; 49(1):156-62. PubMed ID: 23955155
[TBL] [Abstract][Full Text] [Related]
11. Infliximab for the treatment of resistant oral ulcers in Behçet's disease: a case report and review of the literature.
Almoznino G; Ben-Chetrit E
Clin Exp Rheumatol; 2007; 25(4 Suppl 45):S99-102. PubMed ID: 17949561
[TBL] [Abstract][Full Text] [Related]
12. TNF-alpha antagonists and thalidomide for the management of gastrointestinal Behçet's syndrome refractory to the conventional treatment modalities: a case series and review of the literature.
Hatemi I; Hatemi G; Pamuk ON; Erzin Y; Celik AF
Clin Exp Rheumatol; 2015; 33(6 Suppl 94):S129-37. PubMed ID: 26486925
[TBL] [Abstract][Full Text] [Related]
13. The effect of anti-tumour necrosis factor alpha (infliximab) on sight-threatening uveitis in a patient with Behçet's disease.
Morris DS; Gavin MP; Sturrock RD
Adv Exp Med Biol; 2003; 528():557-9. PubMed ID: 12918763
[No Abstract] [Full Text] [Related]
14. [Behcet disease -- case report].
Corduneanu A; Sevciuc R; Gherasim V
Oftalmologia; 2012; 56(3):52-8. PubMed ID: 23713339
[TBL] [Abstract][Full Text] [Related]
15. Remission of Behcet's disease with anti-tumor necrosis factor monoclonal antibody therapy: a case report.
Gulli S; Arrigo C; Bocchino L; Morgante L; Sangari D; Castagna I; Bagnato GF
BMC Musculoskelet Disord; 2003 Aug; 4():19. PubMed ID: 12946278
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial.
Tugal-Tutkun I; Mudun A; Urgancioglu M; Kamali S; Kasapoglu E; Inanc M; Gül A
Arthritis Rheum; 2005 Aug; 52(8):2478-84. PubMed ID: 16052571
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy of infliximab and thalidomide for refractory entero-Behcet's disease: a case report.
Li Y; Han Z; Wang X; Mo Z; Zhang W; Li A; Liu S
BMC Gastroenterol; 2013 Dec; 13():167. PubMed ID: 24321021
[TBL] [Abstract][Full Text] [Related]
18. Mimicry between intestinal Behçet's disease and inflammatory bowel disease.
Rodrigues-Pinto E; Magro F; Pimenta S; Guimarães J; Macedo G
J Crohns Colitis; 2014 Jul; 8(7):714-5. PubMed ID: 24389388
[No Abstract] [Full Text] [Related]
19. Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet's Disease.
Park J; Cheon JH
Gut Liver; 2018 Nov; 12(6):623-632. PubMed ID: 29788675
[TBL] [Abstract][Full Text] [Related]
20. Behçet's ileocolitis: successful treatment with tumor necrosis factor-alpha antibody (infliximab) therapy: report of a case.
Kram MT; May LD; Goodman S; Molinas S
Dis Colon Rectum; 2003 Jan; 46(1):118-21. PubMed ID: 12544532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
